Hostname: page-component-78c5997874-94fs2 Total loading time: 0 Render date: 2024-11-17T03:24:15.522Z Has data issue: false hasContentIssue false

Body mass index and functioning in long-term schizophrenia

Results of the DSP project

Published online by Cambridge University Press:  16 April 2020

Raimo K.R. Salokangas*
Affiliation:
Department of Psychiatry, University of Turku, Psychiatric Clinic, Turku University Central Hospital, Turku Psychiatric Clinic, Kiinamyllynkatu 4e8, FI-20520Turku, Finland
Teija Honkonen
Affiliation:
Finnish Institute of Occupational Health, Topeliuksenkatu 41aA, FI-00250Helsinki, Finland
Eija Stengård
Affiliation:
National Research and Development Centre for Welfare and Health, Health and Social Services, P.O. Box 220, FI-00531Helsinki, Finland
Jarmo Hietala
Affiliation:
Department of Psychiatry, University of Turku, FI-20700Turku, Finland
*
*Corresponding author. Tel.: +358 2 3131 740; fax: +358 2 3132 730. E-mail address: [email protected] (R.K.R. Salokangas).
Get access

Abstract

Objective

The study evaluates the association of body mass index (BMI) with functioning in male and female patients with long-term schizophrenia.

Method

722 long-term schizophrenia patients were interviewed three years after discharge from hospital. Their weight and height were recorded and data on their background, illness history, psychosocial functioning (Global Assessment Scale; GAS), health behaviour, daily doses of neuroleptics, and psychiatric symptoms were collected.

Results

BMI correlated significantly with GAS scores in male (r = 0.202, p = 0.000) but not in female patients. In male patients, BMI associated significantly (p = 0.005) with GAS scores even when the effects of psychiatric symptoms and other confounding variables were taken into account.

Conclusions

In male but not in female long-term patients with schizophrenia, low BMI associates with poor functioning. It is suggested that among male schizophrenia patients, low BMI may be an indicator of poor functioning.

Type
Original article
Copyright
Copyright © Elsevier Masson SAS 2007

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Footnotes

*

Declaration of interest: None.

References

Alanen, Y.O., Räkköläinen, V., Laakso, J., Rasimus, R., Kaljonen, A.Towards need-specific treatment of schizophrenic psychoses. Heidelberg: Springer-Verlag; 1986.CrossRefGoogle ScholarPubMed
Allison, D.B., Casey, D.E.Antipsychotic-induced weight gain: a review of the literature. J Clin Psychiatry 2001;62(Suppl 7):2231.Google ScholarPubMed
Allison, D.B., Fontaine, K.R., Heo, M., Mentore, J.L., Cappelleri, J.C., Chandler, L.P.et al.The distribution of body mass index among individuals with and without schizophrenia. J Clin Psychiatry 1999;60:215220.CrossRefGoogle ScholarPubMed
Angermeyer, M.C., Kühn, L., Goldstein, J.M.Gender and the course of schizophrenia: differences in treated outcomes. Schizophr Bull 1990;16:293307.CrossRefGoogle ScholarPubMed
Basson, B.R., Kinon, B.J., Taylor, C.C., Szymanski, K.A., Gilmore, J.A., Tollefson, G.D.Factors influencing acute weight change in patients with schizophrenia treated with olanzapine, haloperidol, or risperidone. J Clin Psychiatry 2001;62:231238.CrossRefGoogle ScholarPubMed
Endicott, J., Spitzer, R.L., Fleis, J.L., Cohen, J.The Global Assessment Scale. A procedure for measuring overall severity of psychiatric disturbance. Arch Gen Psychiatry 1976;33:766771.CrossRefGoogle ScholarPubMed
Harman, H.H.Modern factor analysis. Chicago; University of Chicago Press; 1976.Google Scholar
Horrobin, D.F.The membrane phospholibid hypothesis as a biochemical basis for the neurodevelopmental concept of schizophrenia. Schizophr Res 1998;30:193208.CrossRefGoogle ScholarPubMed
Kay, S.R., Opler, L.A., Fiszbein, A.Positive and negative syndrome scale (PANSS) rating manual. Bronx: Bronx Psychiatric Center; 1986.Google Scholar
Kinon, B.J., Basson, B.R., Gilmore, J.A., Tollefson, G.D.Long-term olanzepine treatment: weight change and weight-related health factors in schizophrenia. J Clin Psychiatry 2001;62:92100.CrossRefGoogle Scholar
Leung, A., Chue, P.Sex differences in schizophrenia, a review of the literature. Acta Psychiatr Scand Suppl 2000;401:338.CrossRefGoogle ScholarPubMed
Lieberman, J., Chakos, M., Wu, H., Alvir, J., Hoffman, E., Robinson, D.et al.Longitudinal study of brain morphology in first episode schizophrenia. Biol Psychiatry 2001;49:487499.CrossRefGoogle ScholarPubMed
McElroy, S.L., Kotwal, R., Malhotra, S., Nelson, E.B., Keck, P.E., Nemeroff, C.B.Are mood disorders and obesity related? A review for the mental health professionals. J Clin Psychiatry 2004;65:634651.CrossRefGoogle Scholar
Melkersson, K.I., Hulting, A.L., Brismar, K.E.Elevated levels of insulin, leptin, and blood lipids in olanzepine-treated patients with schizophrenia or related psychoses. J Clin Psychiatry 2000;61:742749.CrossRefGoogle ScholarPubMed
Meltzer, H.Y., Perry, E., Jayathilake, K.Clozapine-induced weight gain predicts improvement in psychopathology. Schizophr Res 2003;59:1927.CrossRefGoogle ScholarPubMed
Murray, R.M., Van Os, J.Predictors of outcome in schizophrenia. J Clin Psychopharmacol 18Suppl 11998 2S4S.CrossRefGoogle Scholar
Myers, A., Rosen, J.Obesity stigmatization and coping: relation to mental health symptoms, body image, and self-esteem. Int J Obes Relat Metab Disord 1999;23:221230.CrossRefGoogle ScholarPubMed
Newcomer, J.W.Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs 2005;19(Suppl 1):193.CrossRefGoogle ScholarPubMed
Salokangas, R.K.R., Honkonen, T., Stengård, E., Koivisto, A.-M.Symptom dimensions and their association with outcome and treatment setting in long-term schizophrenia. Results of the DSP project. Nord J Psychiatry 2002;56:319327.CrossRefGoogle ScholarPubMed
Salokangas, R.K.R., Stengård, E., Honkonen, T., Koivisto, A.-M., Saarinen, S.Sairaalasta yhteiskuntaan. Seurantatutkimus sairaalasta kotiuttamisen vaikutuksista skitsofreniapotilaan elämään ja hoitotilanteeseen. (In Finnish)2000 Helsinki: STAKES; Raportteja 248.Google Scholar
Salokangas, R.K.R.Symptom dimensions and outcome in schizophrenia. World Psychiatry 2003;2:172178.Google Scholar
Salokangas, R.K.R.Prognostic implications of the sex of schizophrenic patients. Br J Psychiatry 1983;142:145151.CrossRefGoogle ScholarPubMed
Seeman, M.V.Current outcome in schizophrenia: women vs men. Acta Psychiatr Scand 1986;73:609617.CrossRefGoogle ScholarPubMed
Taylor, D.M., McAskill, R.Atypical antipsychotics and weight gain – a systematic review. Acta Psychiatr Scand 2000;101:416432.CrossRefGoogle ScholarPubMed
Submit a response

Comments

No Comments have been published for this article.